Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.72 |
| ▸ | TNF | P01375 | 4/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.62 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779191 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6778535 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8072134 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8062483 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL9294255 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8077706 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8076183 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6774095 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL757112 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6786397 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-6693105-B1 | USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL | CELL THERAPEUTICS, INC. | 2004-02-17 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6133274-A | TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS | CELL THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6121270-A | N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI | CELL THERAPEUTICS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5866576-A | COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. | CELL THERAPEUTICS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5780476-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS | CELL THERAPEUTICS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | ADORA2B 3204/4885TNF 1369/4885USP2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.